Please login to the form below

Not currently logged in
Email:
Password:

vismodegib

This page shows the latest vismodegib news and features for those working in and with pharma, biotech and healthcare.

NICE backs Pfizer’s Xeljanz for RA

NICE backs Pfizer’s Xeljanz for RA

Roche’s Erivedge (vismodegib) - which was made available via the old CDF in 2013 - is also set to be cut from the scheme, but patients who are currently receiving the drug

Latest news

More from news
Approximately 3 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

  • Curis looks to MedImmune and Takeda for new hires Curis looks to MedImmune and Takeda for new hires

    Curis also worked with Roche to Erivedge (vismodegib), which recently won approval for the treatment of advanced basal cell carcinoma (BCC).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics